Moleculin Biotech (MBRX) Short Interest Ratio & Short Volume → This Wall Street stock prediction just went viral (From Chaikin Analytics) (Ad) Free MBRX Stock Alerts $4.92 +0.07 (+1.44%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Moleculin Biotech Short Interest DataCurrent Short Volume31,100 sharesPrevious Short Volume26,700 sharesChange Vs. Previous Month+16.48%Dollar Volume Sold Short$156,122.00Short Interest Ratio / Days to Cover0.8Last Record DateApril 30, 2024Outstanding Shares2,310,000 sharesFloat Size2,150,000 sharesShort Percent of Float1.45%Today's Trading Volume12,352 sharesAverage Trading Volume30,078 sharesToday's Volume Vs. Average41% Short Selling Moleculin Biotech ? Sign up to receive the latest short interest report for Moleculin Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatMBRX Short Interest Over TimeMBRX Days to Cover Over TimeMBRX Percentage of Float Shorted Over Time Ad Chaikin AnalyticsThis Wall Street stock prediction just went viralPeople around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch just the first 5 minutes of his new prediction Moleculin Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202431,100 shares $156,122.00 +16.5%1.5%0.8 $5.02 4/15/202426,700 shares $119,082.00 -40.7%1.2%0.8 $4.46 3/31/202445,000 shares $265,950.00 +2,042.9%2.1%1.4 $5.91 3/15/20242,100 shares $15,576.75 -98.4%0.1%0.1 $7.42 2/29/2024134,400 shares $84,537.60 -2.4%N/A0.8 $0.63 2/15/2024137,700 shares $68,850.00 -37.4%N/A0.9 $0.50 Get the Latest News and Ratings for MBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024220,000 shares $110,880.00 -8.5%N/A1.2 $0.50 1/15/2024240,300 shares $170,613.00 -23.8%N/A1.3 $0.71 12/31/2023315,300 shares $270,653.52 -7.5%N/A1.6 $0.86 12/15/2023340,800 shares $197,664.00 +35.3%N/A2.1 $0.58 11/30/2023251,900 shares $150,812.53 -15.2%N/A1.7 $0.60 11/15/2023296,900 shares $169,233.00 +59.7%N/A1.9 $0.57 10/31/2023185,900 shares $90,012.78 +131.8%N/A1.5 $0.48 10/15/202380,200 shares $36,090.00 -55.3%N/A0.7 $0.45 9/30/2023179,300 shares $76,650.75 +260.0%N/A1.2 $0.43 9/15/202349,800 shares $19,770.60 +30.7%N/A0.3 $0.40 8/31/202338,100 shares $21,336.00 -75.4%N/A0.2 $0.56 8/15/2023155,100 shares $94,455.90 +15.6%N/A1 $0.61 7/31/2023134,200 shares $84,975.44 +42.6%N/A0.7 $0.63 7/15/202394,100 shares $59,283.00 -20.8%N/A0.5 $0.63 6/30/2023118,800 shares $68,761.44 +611.4%N/A0.4 $0.58 6/15/202316,700 shares $9,853.00 +108.8%N/A0.1 $0.59 5/31/20238,000 shares $5,068.00 -59.4%N/A0 $0.63 5/15/202319,700 shares $12,139.14 +20.9%N/A0.1 $0.62 4/30/202316,300 shares $12,180.99 -30.3%0.1%0.1 $0.75 4/15/202323,400 shares $21,294.00 -14.6%0.1%0.1 $0.91 3/31/202327,400 shares $26,304.00 -26.3%0.1%0.4 $0.96 3/15/202337,200 shares $35,340.00 -13.9%0.1%0.5 $0.95 2/28/202343,200 shares $52,272.00 -30.1%0.2%0.5 $1.21 2/15/202361,800 shares $80,340.00 +56.9%0.2%0.7 $1.30 1/31/202339,400 shares $49,640.06 -49.0%0.1%0.4 $1.26 1/15/202377,200 shares $100,360.00 -34.9%0.3%0.8 $1.30 12/30/2022118,600 shares $125,716.00 +48.3%0.4%1.2 $1.06 12/15/202280,000 shares $110,400.00 -9.7%0.3%0.8 $1.38 11/30/202288,600 shares $127,584.00 +30.3%0.3%0.9 $1.44 11/15/202268,000 shares $64,593.20 +32.0%0.2%0.6 $0.95 10/31/202251,500 shares $51,500.00 -9.8%0.2%0.5 $1.00 10/15/202257,100 shares $57,100.00 -5.3%0.2%0.6 $1.00 9/30/202260,300 shares $63,918.00 -36.4%0.2%0.6 $1.06 9/15/202294,800 shares $134,616.00 -40.0%0.3%1 $1.42Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic MBRX Short Interest - Frequently Asked Questions What is Moleculin Biotech's current short interest? Short interest is the volume of Moleculin Biotech shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 31,100 shares of MBRX short. 1.45% of Moleculin Biotech's shares are currently sold short. Learn More on Moleculin Biotech's current short interest. What is a good short interest ratio for Moleculin Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MBRX shares currently have a short interest ratio of 1.0. Learn More on Moleculin Biotech's short interest ratio. What is a good short interest percentage for Moleculin Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.45% of Moleculin Biotech's floating shares are currently sold short. Is Moleculin Biotech's short interest increasing or decreasing? Moleculin Biotech saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 31,100 shares, an increase of 16.5% from the previous total of 26,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Moleculin Biotech's float size? Moleculin Biotech currently has issued a total of 2,310,000 shares. Some of Moleculin Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Moleculin Biotech currently has a public float of 2,150,000 shares. How does Moleculin Biotech's short interest compare to its competitors? 1.45% of Moleculin Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Moleculin Biotech: MIRA Pharmaceuticals, Inc. (0.42%), Avalo Therapeutics, Inc. (10.13%), Guardion Health Sciences, Inc. (14.33%), Elevai Labs, Inc. (0.48%), ABVC BioPharma, Inc. (7.35%), Monopar Therapeutics Inc. (1.24%), Aeterna Zentaris Inc. (0.34%), Akari Therapeutics, Plc (0.03%), Addex Therapeutics Ltd (1.85%), NuCana plc (1.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Moleculin Biotech stock? Short selling MBRX is an investing strategy that aims to generate trading profit from Moleculin Biotech as its price is falling. MBRX shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Moleculin Biotech? A short squeeze for Moleculin Biotech occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MBRX, which in turn drives the price of the stock up even further. How often is Moleculin Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MBRX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: MIRA Pharmaceuticals Short Squeeze Avalo Therapeutics Short Squeeze Guardion Health Sciences Short Squeeze Elevai Labs Short Squeeze ABVC BioPharma Short Squeeze Monopar Therapeutics Short Squeeze Aeterna Zentaris Short Squeeze Akari Therapeutics Short Squeeze Addex Therapeutics Short Squeeze NuCana Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MBRX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News